Pfizer optimistic about drug candidates in late-stage development

04/2/2009 | Wall Street Journal, The · Reuters

In a periodic update, Pfizer presented a positive outlook for some of its drugs entering late-stage development, including a JAK inhibitor for rheumatoid arthritis, Alzheimer's disease drug Dimebon and Tanezumab, a monoclonal antibody to treat pain. In a separate announcement, the company said it is halting a trial of Sutent after the cancer medicine failed to outperform chemotherapy drug capecitabine in improving patients' condition.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC